Butler National CEO details ongoing medical treatment

Butler National Corporation disclosed that Chief Executive Officer Christopher J. Reedy is undergoing a new course of medical treatment following recent consultations with physicians at the Mayo Clinic.

Rhea-AI Filing Summary

Butler National Corporation disclosed that Chief Executive Officer Christopher J. Reedy is undergoing a new course of medical treatment following recent consultations with physicians at the Mayo Clinic. Reedy previously received a cancer diagnosis in 2019 and has had ongoing follow-up visits since then.

He stated that he will continue serving as Chief Executive Officer and remain actively engaged with the company’s operations, leadership team, employees, and Board of Directors, although treatment may periodically require time away from the office. The Executive Chairman and Lead Independent Director both expressed support for Reedy and confidence in the strength of Butler National’s leadership team and the company’s ongoing operational and strategic priorities.

Insights

Corporate governance analyst

CEO health update is disclosed, but leadership continuity is emphasized.

Butler National provides a formal update that CEO Christopher J. Reedy is undergoing a new medical treatment after consultations at the Mayo Clinic, following an earlier cancer diagnosis in 2019. This type of disclosure addresses potential investor concerns about leadership stability.

The company states that Reedy will continue as Chief Executive Officer and stay actively engaged with operations, supported by the executive team and Board. Statements from the Executive Chairman and Lead Independent Director highlight confidence in both his leadership and the existing management structure.

From a governance standpoint, the filing underscores succession resilience by stressing the strength of the broader leadership team and continued focus on operational and strategic priorities. Future company filings may provide additional updates if there are changes to Reedy’s role or time commitments.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Item 8.01, Other Events, Emerging growth company, Executive Chairman, +1 more

5 terms

Item 8.01 regulatory

"Item 8.01 | Other Events On June 1, 2026, Christopher J. Reedy..."

Item 8.01 is the section of a company’s current report to regulators used to disclose “other events” that are important but don’t fit into the report’s specific boxes. Think of it as a public bulletin board where a company posts unexpected or miscellaneous developments—legal updates, product news, or management changes—that investors need to know because they can change how the market values the company or influence investment decisions.

Other Events regulatory

"Item 8.01 | Other Events On June 1, 2026, Christopher J. Reedy..."

Emerging growth company regulatory

"Emerging growth company [TABLE] Item 8.01 | Other Events..."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Executive Chairman financial

"Executive Chairman Jeffrey D. Yowell stated, “Chris is a valued leader..."

An executive chairman is the board leader who also takes an active role in running the company, combining oversight of the board with hands-on involvement in strategy and major decisions. For investors, this matters because it concentrates influence in one person—like a team captain who both sets the game plan and plays on the field—so their judgment can speed decisions but also increases governance and succession risk that can affect stock value.

Lead Independent Director financial

"Lead Independent Director Joseph P. Daly added, “We remain confident..."

A lead independent director is a board member who is not part of company management and is chosen to coordinate and represent the other independent directors, often running sessions without the CEO, helping set meeting agendas, and serving as a liaison between shareholders and the board. For investors, this role signals stronger, more balanced oversight—like a neutral referee who helps ensure decisions are fair, transparent and focused on protecting shareholder interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Butler National (BUKS) disclose about its CEO in this 8-K?

Butler National disclosed that CEO Christopher J. Reedy is undergoing a new course of medical treatment after consultations at the Mayo Clinic. He previously had a cancer diagnosis in 2019 and has continued regular follow-up visits since then, prompting this updated communication.

Will Butler National (BUKS) CEO Christopher Reedy remain in his role?

Yes. Christopher J. Reedy stated he will continue serving as Butler National’s Chief Executive Officer. He plans to remain actively engaged with the leadership team, employees, and Board, even though his treatment may periodically require time away from the office.

How might Christopher Reedy’s treatment affect Butler National’s daily operations?

The company notes that certain aspects of Reedy’s treatment may require time away from the office. However, Butler National emphasizes that its executive leadership team and Board will continue working closely together to support ongoing operations, strategic initiatives, and long-term objectives.

What support did Butler National’s Board express regarding the CEO’s treatment?

Executive Chairman Jeffrey D. Yowell called Reedy a valued leader and friend and said the Board fully supports him during treatment. Lead Independent Director Joseph P. Daly expressed confidence in Reedy’s leadership and appreciation for the management team’s support and commitment during this period.

What document was attached to Butler National’s 8-K about the CEO’s health?

The filing includes Exhibit 99.1, which is an email from CEO Christopher J. Reedy to Butler National employees. In it, he explains his new course of medical treatment, reaffirms his ongoing role, and thanks employees for their dedication and support.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 12:41 PM Learn about SEC filing dates

false000001584700000158472026-06-012026-06-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) June 1, 2026

BUTLER NATIONAL CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Kansas

(State or Other Jurisdiction of Incorporation)

			0-1678  (Commission File Number)			41-0834293  (IRS Employer Identification No.)
			One Aero Plaza, New Century, Kansas  (Address of Principal Executive Offices)			66031  (Zip Code)

913-780-9595

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
None			None			None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01			Other Events
			On June 1, 2026, Christopher J. Reedy, Chief Executive Officer of Butler National Corporation (“Butler National”), sent an email to Butler National employees regarding a course of medical treatment he is currently undergoing following recent consultations with his physicians at the Mayo Clinic. A copy of the email is attached as Exhibit 99.1. Mr. Reedy will continue serving as Chief Executive Officer and will remain actively engaged with Butler National’s operations, leadership team, and Board of Directors. While certain aspects of his treatment may periodically require time away from the office, Butler National’s executive leadership team and Board will continue working closely together to support ongoing operations, strategic initiatives, and long-term objectives. Executive Chairman Jeffrey D. Yowell stated, “Chris is a valued leader and friend, and the Board fully supports him during this treatment process. Butler National has a strong leadership team in place, and we will continue working collaboratively to advance our operational and strategic priorities.” Lead Independent Director Joseph P. Daly added, “We remain confident in Chris’ leadership and are appreciative of the support and commitment demonstrated across the Butler National management team during this period.”
Item 9.01			Financial Statements and Exhibits
Exhibit 99.1			Email of Christopher J. Reedy, Chief Executive Officer of Butler National
Exhibit 104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			BUTLER NATIONAL CORPORATION (Registrant)
June 1, 2026 Date			/s/ Christopher J. Reedy Christopher J. Reedy (Chief Executive Officer, President and Secretary)

Exhibit 99.1

To: Butler National Employees

From: Christopher J. Reedy

Date: June 1, 2026

Re: Update from Chris Reedy

To my friends and colleagues,

I wanted to personally share that I am currently undergoing a new course of medical treatment following recent consultations with my physicians at the Mayo Clinic. As many of you know, I have continued regular follow-up visits since my cancer diagnosis in 2019.

While this treatment may periodically require me to spend time away from the office, I will continue serving as Butler National’s Chief Executive Officer and remain actively engaged with our leadership team, employees, and Board of Directors throughout this process.

I am grateful for the support and encouragement I have received from the Board and from so many across the organization. Butler National has an outstanding leadership team, and I am confident in the continued momentum of our business and the opportunities ahead of us.

Thank you for your continued dedication, professionalism, and support. I look forward to continuing to work with all of you, whether in person or remotely, in the weeks and months ahead.

Best regards,

Chris

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 3.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 18.7 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 10.7 KB